Target type: biologicalprocess
The controlled breakdown of the basement membrane in the context of a normal process such as imaginal disc eversion. [GOC:sart, PMID:17301221]
Basement membrane disassembly is a complex process involving the coordinated action of multiple enzymes and cellular components. It is essential for various physiological processes, including tissue remodeling, wound healing, and embryonic development.
The basement membrane, a specialized extracellular matrix, provides structural support and acts as a barrier between different tissues. It is composed of several key components, including collagen IV, laminin, nidogen, and perlecan.
During disassembly, the following steps occur:
1. **Activation of Matrix Metalloproteinases (MMPs):** MMPs are a family of zinc-dependent endopeptidases that degrade components of the extracellular matrix. Specific MMPs, such as MMP-2 and MMP-9, are known to degrade collagen IV and laminin, respectively.
2. **Cleavage of Basement Membrane Components:** Once activated, MMPs cleave the structural components of the basement membrane, disrupting its integrity. Collagen IV is broken down into smaller fragments, while laminin is cleaved at specific sites.
3. **Release of Growth Factors and Cytokines:** The degradation of the basement membrane releases various growth factors and cytokines, which can influence cell migration, proliferation, and differentiation.
4. **Cellular Adhesion and Migration:** The disruption of the basement membrane allows cells to detach and migrate through the ECM. This is crucial for processes like wound healing and embryonic development.
5. **Reorganization of the Basement Membrane:** As cells migrate, the basement membrane may undergo reorganization and repair. New ECM components can be synthesized and deposited, leading to the formation of a new basement membrane.
**Factors Regulating Basement Membrane Disassembly:**
- **Growth factors:** Several growth factors, including transforming growth factor-beta (TGF-beta) and fibroblast growth factor (FGF), can stimulate MMP expression and activate the disassembly process.
- **Cytokines:** Inflammatory cytokines like TNF-alpha and IL-1 can also induce basement membrane disassembly.
- **Mechanical forces:** Physical forces, such as stretching or compression, can trigger MMP activation and contribute to basement membrane disassembly.
**Disruption of Basement Membrane Disassembly:**
- **Abnormal basement membrane degradation:** Uncontrolled or excessive degradation of the basement membrane can lead to various diseases, including cancer metastasis and inflammatory diseases.
- **Defective basement membrane repair:** Impaired repair mechanisms can result in weakened basement membranes, leading to tissue fragility and dysfunction.
Overall, basement membrane disassembly is a tightly regulated process involving a delicate balance between degradation and repair. It is crucial for normal tissue function and plays a significant role in a variety of physiological and pathological processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cathepsin S | A cathepsin S that is encoded in the genome of human. [PRO:DNx, UniProtKB:P25774] | Homo sapiens (human) |
Chymase | A chymase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P23946] | Homo sapiens (human) |
Serine protease hepsin | A serine protease hepsin that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05981] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
bis(5-amidino-2-benzimidazolyl)methane | bis(5-amidino-2-benzimidazolyl)methane: aromatic diamidine which has a significant suppressive effect on the cytopathology & yield of respiratory synctial (RS) virus; RN given refers to parent cpd | ||
camostat | camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients. | benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide | anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor |
gabexate | Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. | benzoate ester | |
nafamostat | nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic | benzoic acids; guanidines | |
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
Pyrrolidine-1-carbonitrile | pyrrolidines | ||
6-chloroindole | indoles | ||
zpck | ZPCK: alkylates histidine residue at active center of bovine chymotrypsin | ||
5-amidinoindole | |||
e 64 | E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-) | dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion | antimalarial; antiparasitic agent; protease inhibitor |
5-chlorooxindole | 5-chlorooxindole: structure in first source | ||
dabigatran | dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. | aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines | anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor |
2-oxindole | 2-oxindole: RN given refers to parent cpd; structure indolin-2-one : An indolinone carrying an oxo group at position 2. | gamma-lactam; indolinone | |
bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
tosylphenylalanyl chloromethyl ketone | N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone. Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process. | alpha-chloroketone; sulfonamide | alkylating agent; serine proteinase inhibitor |
benzamidine | carboxamidinium ion | ||
telaprevir | cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines | antiviral drug; hepatitis C protease inhibitor; peptidomimetic | |
relacatib | relacatib: a cathepsin K inhibitor; structure in first source | ||
a-705253 | A-705253: structure in first source | ||
l 006235 | |||
l-873724 | L-873724: a selective inhibitor of cathepsin K; structure in first source | ||
odanacatib | odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source | ||
balicatib | balicatib: cathepsin K inhibitor | ||
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | tripeptide; ureas | antiviral drug; hepatitis C protease inhibitor; peptidomimetic |
epoxomicin | morpholines; tripeptide | proteasome inhibitor | |
mk-7009 | vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan. vaniprevir: inhibits hepatitis C virus NS3/4a protease | azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide | antiviral drug; hepatitis C protease inhibitor |
delanzomib | C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative | antineoplastic agent; apoptosis inducer; proteasome inhibitor | |
simeprevir | azamacrocycle; lactam | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
rpx7009 | RPX7009: a beta-lactamase inhibitor; structure in first source | ||
ly3000328 | LY3000328: a cathepsin S inhibitor |